NPS-2143 (NPS2143, CAS: 284035-33-2) is a small molecule inhibitor of the calcium-sensing receptor (CaSR). It has been studied as a potential treatment for various conditions related to calcium metabolism, including hyperparathyroidism and osteoporosis. In this article, we will discuss the chemical properties of NPS-2143, its health benefits, potential effects, mechanism of action, safety profile, dosing information, and more.
Chemical Properties: The chemical name of NPS-2143 is 2-chloro-N-((1R,2R)-2-(4-hydroxyphenyl)-1-methylpropyl)-1H-indole-5-sulfonamide. Its molecular formula is C19H20ClN3O3S, and its formula weight is 413.9 g/mol. The CAS number of NPS-2143 is 284035-33-2.
Top Ten Keywords from Google and Synonyms:
Health Benefits: NPS-2143 has shown potential health benefits for various conditions related to calcium metabolism. It works by inhibiting the calcium-sensing receptor, which is involved in regulating calcium levels throughout the body. By blocking this receptor, NPS-2143 may help to reduce excessive calcium levels and potentially improve bone health.
Potential Effects: NPS-2143 has been studied in preclinical and clinical trials for its potential effects on various conditions related to calcium metabolism. Some of its key effects include:
Product Mechanism: NPS-2143 works by inhibiting the calcium-sensing receptor, which is found throughout the body in various tissues, including the parathyroid gland, kidney, and bone. When calcium levels are high, the receptor is activated and signals the body to reduce calcium absorption and increase calcium excretion. By blocking the receptor, NPS-2143 can disrupt this signaling pathway and potentially reduce excessive calcium levels.
Safety: Like all drugs, NPS-2143 has some potential safety concerns. However, the safety of the product is still being investigated and it should not be considered as a fully approved medication yet. Some of the known safety issues include:
Side Effects: Some of the possible side effects of NPS-2143 include gastrointestinal disturbances, headache, dizziness, weakness, and fatigue. More serious adverse events reported in clinical trials include QT prolongation and arrhythmias. It is essential for healthcare providers to monitor patients closely when they are on this medication.
Dosing Information: The optimal dosages of NPS-2143 are still being studied but initial reports suggest that doses ranging from 10 to 100 mg/day might be useful, depending on the indication for use.
Conclusion: In conclusion, NPS-2143 is a promising small molecule inhibitor that has shown potential as a treatment for various conditions related to calcium metabolism. It works by inhibiting the calcium-sensing receptor, which is involved in regulating calcium levels throughout the body. Although still in early stages of clinical development, NPS-2143 has shown efficacy in reducing excessive calcium levels in hyperparathyroidism, improving bone mineral density in osteoporosis, and protecting against renal damage caused by secondary hyperparathyroidism. Further research is needed to determine its long-term safety and effectiveness